SETD2 and prostate carcinoma: Huairui Yuan et al. reported that SETD2 methylates EZH2 which promotes EZH2 degradation and SETD2 deficiency promotes a Polycomb-repressive chromatin state that renders cells to obtain metastatic potentiality in prostate cancer [25].